Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | MYLK | Q15746 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235658 | 0.87 | MAPK1 (0.57) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6236659 | 0.81 | MAPK1 (0.57) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6240041 | 0.79 | MAPK1 (0.59) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6235598 | 0.79 | MAPK1 (0.56) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6235081 | 0.79 | HSD17B10 (0.67) | MAPK1HSD17B10CYP2C9NR1I2CNR2 | |
| SCHEMBL6231919 | 0.78 | MAPK1 (0.64) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6232817 | 0.78 | MAPK1 (0.64) | MAPK1HSD17B10CYP2C9NR1I2MYLK | |
| SCHEMBL6242212 | 0.77 | MAPK1 (0.53) | MAPK1HSD17B10CYP2C9NR1I2CNR2 | |
| SCHEMBL8239358 | 0.77 | HSD17B10 (0.74) | MAPK1HSD17B10CYP2C9NR1I2MAPT | |
| SCHEMBL6737830 | 0.77 | MAPK1 (0.61) | MAPK1HSD17B10CYP2C9NR1I2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.